JP2025170240A5 - - Google Patents
Info
- Publication number
- JP2025170240A5 JP2025170240A5 JP2025122950A JP2025122950A JP2025170240A5 JP 2025170240 A5 JP2025170240 A5 JP 2025170240A5 JP 2025122950 A JP2025122950 A JP 2025122950A JP 2025122950 A JP2025122950 A JP 2025122950A JP 2025170240 A5 JP2025170240 A5 JP 2025170240A5
- Authority
- JP
- Japan
- Prior art keywords
- adenosine deaminase
- fusion protein
- base editor
- domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897777P | 2019-09-09 | 2019-09-09 | |
| US62/897,777 | 2019-09-09 | ||
| USPCT/US2020/018195 | 2020-02-13 | ||
| PCT/US2020/018195 WO2020168135A1 (en) | 2019-02-13 | 2020-02-13 | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| JP2022514994A JP7717684B2 (ja) | 2019-09-09 | 2020-09-09 | 新規核酸塩基エディター及びその使用方法 |
| PCT/US2020/049975 WO2021050571A1 (en) | 2019-09-09 | 2020-09-09 | Novel nucleobase editors and methods of using same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514994A Division JP7717684B2 (ja) | 2019-09-09 | 2020-09-09 | 新規核酸塩基エディター及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025170240A JP2025170240A (ja) | 2025-11-18 |
| JP2025170240A5 true JP2025170240A5 (https=) | 2026-03-09 |
Family
ID=74867196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514994A Active JP7717684B2 (ja) | 2019-09-09 | 2020-09-09 | 新規核酸塩基エディター及びその使用方法 |
| JP2025122950A Pending JP2025170240A (ja) | 2019-09-09 | 2025-07-23 | 新規核酸塩基エディター及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514994A Active JP7717684B2 (ja) | 2019-09-09 | 2020-09-09 | 新規核酸塩基エディター及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230075877A1 (https=) |
| EP (1) | EP4028026A4 (https=) |
| JP (2) | JP7717684B2 (https=) |
| KR (1) | KR20220076467A (https=) |
| CN (1) | CN114667149A (https=) |
| AU (1) | AU2020344547A1 (https=) |
| CA (1) | CA3153624A1 (https=) |
| WO (1) | WO2021050571A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| KR20210126680A (ko) * | 2019-02-13 | 2021-10-20 | 빔 테라퓨틱스, 인크. | 알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법 |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| CA3128755C (en) | 2019-02-13 | 2024-06-04 | Beam Therapeutics Inc. | Compositions and methods for treating hemoglobinopathies |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| EP4313118A4 (en) * | 2021-03-26 | 2025-06-18 | Beam Therapeutics Inc. | ADENOSINE DEAMINASE VARIANTS AND THEIR USES |
| WO2022240858A1 (en) | 2021-05-10 | 2022-11-17 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| WO2023275892A1 (en) * | 2021-06-29 | 2023-01-05 | Council Of Scientific & Industrial Research | Engineered fncas9 and uses thereof |
| US20240352439A1 (en) * | 2021-09-03 | 2024-10-24 | The University Of Chicago | Polypeptides and methods for modifying nucleic acids |
| CA3231679A1 (en) * | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Hbb-modulating compositions and methods |
| EP4409000A1 (en) | 2021-09-28 | 2024-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Base editing approaches for the treatment of beta-hemoglobinopathies |
| WO2023099591A1 (en) | 2021-12-01 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer |
| WO2023141590A2 (en) | 2022-01-21 | 2023-07-27 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| WO2023144104A1 (en) | 2022-01-25 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Base editing approaches for the treatment of βeta-thalassemia |
| WO2023196802A1 (en) | 2022-04-04 | 2023-10-12 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
| JP2025515503A (ja) | 2022-04-28 | 2025-05-15 | ザ ブロード インスティテュート，インコーポレーテッド | 塩基エディタをコードするａａｖベクターおよびその使用 |
| US20250223326A1 (en) | 2022-05-10 | 2025-07-10 | Institut National de la Santé et de la Recherche Médicale | Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells |
| US20250241956A1 (en) | 2022-05-10 | 2025-07-31 | Institut National de la Santé et de la Recherche Médicale | Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from beta-thalassemia |
| WO2024018056A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia |
| CN115820691B (zh) * | 2022-07-25 | 2023-08-22 | 安徽农业大学 | 一种基于LbCpf1变体的水稻碱基编辑系统和应用 |
| WO2024040083A1 (en) | 2022-08-16 | 2024-02-22 | The Broad Institute, Inc. | Evolved cytosine deaminases and methods of editing dna using same |
| WO2024040874A1 (zh) * | 2022-08-22 | 2024-02-29 | 山东舜丰生物科技有限公司 | 突变的Cas12j蛋白及其应用 |
| KR20250075667A (ko) * | 2022-09-23 | 2025-05-28 | 기초과학연구원 | 신규한 아데닌 탈아미노효소 변이체 및 이를 사용한 염기 교정 방법 |
| JP2026506554A (ja) | 2023-02-06 | 2026-02-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 多重塩基編集による遺伝子改変造血幹細胞の濃縮 |
| WO2024230760A1 (zh) * | 2023-05-09 | 2024-11-14 | 北京齐禾生科生物科技有限公司 | 一种可作用于dna的腺苷脱氨酶及其应用 |
| CN117965505A (zh) * | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
| KR20260044217A (ko) | 2023-07-25 | 2026-04-01 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Cas 엔도뉴클레아제 및 관련 방법 |
| WO2025059520A1 (en) * | 2023-09-15 | 2025-03-20 | Beam Therapeutics Inc. | Compositions and methods for base editing a phenylalanine hydroxylase polynucleotide |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| CN120536418A (zh) * | 2024-02-26 | 2025-08-26 | 尧唐(上海)生物科技有限公司 | 一种脱氨酶变体、包含其的碱基编辑器及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007765B1 (pt) * | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| CN110214183A (zh) * | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| US11242542B2 (en) * | 2016-10-07 | 2022-02-08 | Integrated Dna Technologies, Inc. | S. pyogenes Cas9 mutant genes and polypeptides encoded by same |
| KR102622411B1 (ko) * | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| EP3538561A4 (en) * | 2016-11-11 | 2020-10-21 | The Regents of The University of California | RNA-GUIDED VARIANT POLYPEPTIDES AND THEIR METHODS OF USE |
| KR20250107288A (ko) * | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| CN109957569B (zh) * | 2017-12-22 | 2022-10-25 | 苏州齐禾生科生物科技有限公司 | 基于cpf1蛋白的碱基编辑系统和方法 |
| CN109295186B (zh) * | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
-
2020
- 2020-09-09 AU AU2020344547A patent/AU2020344547A1/en active Pending
- 2020-09-09 EP EP20863422.0A patent/EP4028026A4/en active Pending
- 2020-09-09 WO PCT/US2020/049975 patent/WO2021050571A1/en not_active Ceased
- 2020-09-09 US US17/641,343 patent/US20230075877A1/en active Pending
- 2020-09-09 CA CA3153624A patent/CA3153624A1/en active Pending
- 2020-09-09 CN CN202080077983.2A patent/CN114667149A/zh active Pending
- 2020-09-09 KR KR1020227011386A patent/KR20220076467A/ko active Pending
- 2020-09-09 JP JP2022514994A patent/JP7717684B2/ja active Active
-
2025
- 2025-07-23 JP JP2025122950A patent/JP2025170240A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025170240A5 (https=) | ||
| JP2022546608A5 (https=) | ||
| JP2025026840A5 (https=) | ||
| WO2019042284A1 (en) | FUSION PROTEINS FOR ENHANCED PRECISION IN THE BASIC EDITION | |
| EP3536796A1 (en) | Gene knockout method | |
| JP2022520081A5 (https=) | ||
| JP2021523736A5 (https=) | ||
| JP2016165307A5 (https=) | ||
| KR20200121782A (ko) | 아데노신 염기 편집제의 용도 | |
| JP2019536425A5 (https=) | ||
| JP2022519882A5 (https=) | ||
| JP2022532139A5 (https=) | ||
| JP2025102768A5 (https=) | ||
| JP2023545497A5 (https=) | ||
| US20220064651A1 (en) | Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase | |
| WO2023097316A1 (en) | Engineered crispr/cas12a effector proteins, and uses thereof | |
| JP2021522825A5 (https=) | ||
| WO2024125221A1 (zh) | 一种碱基编辑系统及碱基编辑方法 | |
| US20250163410A1 (en) | Crispr-transposon systems for dna modification | |
| JP7109009B2 (ja) | 遺伝子ノックアウト方法 | |
| WO2025045078A1 (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| WO2025045079A1 (zh) | 一种基于rna特异性脱氨酶突变体及其应用 | |
| US20210395774A1 (en) | Novel virus vector and methods for producing and using same | |
| US20230220361A1 (en) | Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells | |
| EP4665406A1 (en) | Crispr-transposon systems and components |